BioSig Technologies (NASDAQ: BSGM) changed -0.46% to recent value of $8.62. The stock transacted 107004 shares during most recent day however it has an average volume of 247.92K shares. It spotted trading -13.54% off 52-week high price. On the other end, the stock has been noted 146.29% away from the low price over the last 52-weeks.
BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing technology platform designed to address an unmet need for the electrophysiology (EP) marketplace, reported that Ms. Manasi Patwardhan joined the Company as Director of Strategic Planning.
Ms. Patwardhan brings to BioSig over 18 years of program management and product development experience with several Fortune 500 companies in the medical technology, pharma and healthcare verticals. A biomedical engineer by training, Ms. Patwardhan’s core competencies span manufacturing and vendor management, systems engineering, cross-functional team leadership and process improvements. Most recently, Ms. Patwardhan was in a technical program management role at Verily Life Sciences, LLC, an Alphabet, Inc. company, a role, in which she led hardware development for a class III therapy technology program as well as supply-chain and vendor management. Prior to that, Ms. Patwardhan was employed by Boston Scientific – Neuromodulation, where she was responsible for delivering a range of technology and product development programs, including commercially launched products in the Spinal Cord Stimulation portfolio as well as a connected health eco system. Earlier in her career Ms. Patwardhan was with Medtronic Diabetes, where she led product development efforts for class II therapy, diagnostic and combination products. Her work involved the delivery of engineering solutions from cross-functional teams comprising human factors, marketing, industrial design, hardware and software design and third-party vendors. Ms. Patwardhan holds a Master of Science in Biomedical Engineering from the University of Southern California Los Angeles and Bachelor of Engineering, Chemical Engineering from University of Pune, India.
Kenneth L. Londoner, Founder, Chairman and CEO of BioSig Technologies, Inc stated “Manasi impressed us with her accomplishments in strategic delivery of complex engineering projects. Her expertise in successfully navigating the fast-paced product development environment will be of significant value to our growing operations,”.
BSGM . Its earnings per share (EPS) expected to touch remained -17.30% for this year .
The company has 20.38M of outstanding shares and 13.67M shares were floated in the market. According to the most recent quarter its current ratio was 11 that represents company’s ability to meet its current financial obligations. The price moved ahead of 0.75% from the mean of 20 days, 10.11% from mean of 50 days SMA and performed 51.43% from mean of 200 days price. Company’s performance for the week was -1.03%, 26.21% for month and YTD performance remained 101.87%.
Sam Leventhal is a self-taught investor and follows the value investing approach to picking stocks. He possesses over 10 years of investment experience, an M.B.A. from Louisiana State University, and is also certified in Risk Management Assurance. Sam is a Certified Internal Auditor, Data Miner, and author with a career broadly spanning over multiple business areas. He has exploited those observations and developed investment tactics within a fundamentally sound long-term investment strategy. He currently covers Dividend News category for our site.
Email Contact – Sam@newsleading.info
Address: 1894 MacLaren Street, Ottawa, Ontario